Document is current
Any future updates will be listed below
-
Authors
Gulikers, Judith L. https://orcid.org/0000-0002-8844-6992
Otten, Leila-Sophie https://orcid.org/0000-0002-1225-4740
Hendriks, Lizza E. L. https://orcid.org/0000-0002-3521-2535
Winckers, Kristien
Henskens, Yvonne
Leentjens, Jenneke
van den Heuvel, Michel M.
ter Heine, Rob
Croes, Sander
Piet, Berber https://orcid.org/0000-0002-9069-3597
van Geel, Robin M. J. M. https://orcid.org/0000-0003-1880-8131
-
Funding
Funding for this research was provided by:
Funded by Academic Alliance Fund
- License Information
-
More Information
Article History
Received: 8 April 2024
Revised: 22 May 2024
Accepted: 29 May 2024
First Online: 11 June 2024
Competing interests
: Dr. LEL Hendriks reports grants contracts or research funding from Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Pfizer, Novartis. Gilead under negotiation. All payments were paid to the institution. All unrelated to this work. Advisory boards: Amgen, Boehringer Ingelheim, Lilly, Novartis, Pfizer, Takeda, Merck, Janssen, MSD, Anheart. All payments were paid to the institution. Member guideline committees: Dutch guidelines on NSCLC, brain metastases and leptomeningeal metastases (self), ESMO guidelines on metastatic NSCLC and systemic therapy, vice-chair scientific committee Dutch Thoracic Group SCLC (non-financial). Other (non-financial): secretary NVALT studies foundation, subchair EORTC metastatic NSCLC systemic therapy, vice-chair of scientific committee Dutch Thoracic Group. Local PI of clinical trials: AstraZeneca, GSK, Novartis, Merck, Roche, Takeda, Blueprint, Mirati, Abbvie, Gilead, MSD, Merck. All payments to the institution. Speaker educationals/webinars: AstraZeneca, Bayer, Lilly, MSD, high5oncology, Takeda, Janssen, GSK, Sanofi, Pfizer (Inst), Medtalks, Benecke, VJOncology, Medimix (self). All payments were paid to the institution with the exception of Medtalks, Benecke, VJOncology, Medimix. Dr. J Leentjens reports grants or contracts from BMS-Pfizer, Viatris, and AstraZeneca, all unrelated to this work and paid to her institution. Dr. R ter Heine has received research funding from AMGEN for a clinical study investigating the interaction between sotorasib and rivaroxaban. All other authors declare that they have no known competing financial interests.
: Ethics approval was given by the medical ethical committee of Maastricht UMC+ (NL78003.068.21). All participating patients signed informed consent before entering the study.
: All participating patients signed informed consent before entering the study and their data were pseudo-anonymized.
